SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

Article citations

More>>

London, C.A., Bernabe, L.F., Barnard, S., Kisseberth, W.C., Borgatti, A., Henson, M., Wilson, H., Jensen, K., Ito, D., Modiano, J.F., Bear, M.D., Pennell, M.L., Saint-Nartin, J.R., Mccauley, D., Kauffman, M. and Shacham, S. (2014) Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study. PLoS ONE, 9, e87585.
http://dx.doi.org/10.1371/journal.pone.0087585

has been cited by the following article:

  • TITLE: Antitumor Effects and Acute Oral Toxicity Studies of a Plant Extract Mixture Containing Rhus verniciflua and Some Other Herbs

    AUTHORS: Wataru Hiruma, Kohei Suruga, Kazunari Kadokura, Tsuyoshi Tomita, Ayaka Miyata, Yoshihiro Sekino, Masahiko Kimura, Nobuo Yamaguchi, Yasuhiro Komatsu, C. A. Tony Buffington, Nobufumi Ono

    KEYWORDS: Rhus verniciflua, Antitumor, Antiproliferation, Acute Toxicity

    JOURNAL NAME: Open Journal of Immunology, Vol.5 No.1, March 27, 2015

    ABSTRACT: A novel antitumor agent was developed from six kinds of herbs containing Rhus verniciflua (Rv-PEM01). The components were traditionally established for each formula for traditional medicine. The formula was designed to affect antitumor effect as well as maintain host immune functions. First, we investigated the antiproliferative activities of Rv-PEM01 on human and canine tumor cell lines in vitro, and on antitumor effects using BALB/cAJcl-nu/nu mice in vivo. Acute oral toxicity of Rv-PEM01 was also investigated in vivo in ddY mice. Rv-PEM01 exhibited antiproliferative activities against PC-3 (IC50: 0.328 ± 0.081 mg/ml), A549 (IC50: 0.520 ± 0.070 mg/ml), D-17 (IC50: 0.124 ± 0.037 mg/ml) and MRC-5 (IC50: 0.505 ± 0.058 mg/ml) cells. Luteolin 7-β-D-glucopyranoside and apigenin 7-β-D-glucopyranoside were identified as the main active compounds in Rv-PEM01 by HPLC analysis. The single dose toxicity study of Rv-PEM01 did not result in any deaths or abnor-malities in daily behavior, body weight gain, or anatomical observations at necropsy. Thus, so we could not calculate the 50% lethal dose (LD50) in mice, but it would be higher than 5.0 g/kg. Treat- ment with Rv-PEM01 at a dose of 2.5 g/kg tended to show antitumor activities on mice bearing Colon26 tumors compared with the control group. It was concluded that the formula was a safe antitumor agent with no side effects on mouse physiological function as judged by survival and organ weight.